Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma.
|Articles|October 5, 2010
Common Testicular Cancer Medications
Advertisement
Testosterone Gel (AndroGel)
Bleomycin Sulfate (Blenoxane Injection Powder)
Dactinomycin (Cosmegen Injection Powder)
Etoposide Phosphate (Etoposphos Injection Powder)
Advertisement
Related to this article
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
“The more representation, the more people we have participating in clinical trials, the more applicable the data,” said Patricia A. Robinson, MD.
In the phase 3 TANGENT trial, an 8-week course of emactuzumab improved objective response rate vs placebo in patients with tenosynovial giant cell tumor.
In an exploratory KEYNOTE-B15 analysis, ctDNA clearance was higher with enfortumab vedotin plus pembrolizumab than with cisplatin and gemcitabine.
Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer.
Adding pembrolizumab to carboplatin and etoposide improved response rates and OS vs chemotherapy alone in metastatic NEPC in KEYNOTE-365 cohort I.
Posters covered a companion diagnostic for niraparib plus AAP, response biomarkers for radioligand therapy, and genomic profile differences in metastatic CRPC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
2
Adjuvant Ribociclib Improves OS at 6 Years in HR+/HER2- Early Breast Cancer
3
Pembrolizumab Plus Chemo Shows Encouraging Activity in NEPC
4
Extended Letrozole Sustains DFS Benefit at 15 Years in HR+ Breast Cancer
5